Optimal duration of additional therapy after favorable response to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised trial

被引：0
|
作者：
Enomoto, Masaru [1 ]
Tamori, Akihiro [1 ]
Toyama, Madoka [1 ]
Hayashi, Kohmoto Takehiro [1 ]
Morikawa, Hiroyasu [1 ]
Jomura, Hisato [1 ]
Habu, Daiki [1 ]
Sakaguchi, Hiroki [1 ]
Takeda, Tadashi [1 ]
Shiomi, Susumu [2 ]
Nishiguchi, Shuhei [3 ]
Kawada, Norifumi [1 ]
机构：
[1] Osaka City Univ, Sch Med, Dept Hepatol, Osaka, Japan
[2] Osaka City Univ, Sch Med, Dept Nucl Med, Osaka, Japan
[3] Hyogo Med Univ, Dept Internal Med, Osaka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A250 / A250
页数：1
相关论文
共 50 条
  • [21] Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    Bonino, F.
    Marcellin, P.
    Lau, G. K. K.
    Hadziyannis, S.
    Jin, R.
    Piratvisuth, T.
    Germanidis, G.
    Yurdaydin, C.
    Diago, M.
    Gurel, S.
    Lai, M-Y
    Brunetto, M. R.
    Farci, P.
    Popescu, M.
    McCloud, P.
    GUT, 2007, 56 (05) : 699 - 705
  • [22] Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitis B
    Lens, S.
    Garcia-Lopez, M.
    Bonacci, M.
    Rodriguez-Tajes, S.
    Marino, Z.
    Perpinan, E.
    Kotsoudakis, G.
    Testoni, B.
    Rodriguez-Frias, F.
    Buti, M.
    Zoulim, F.
    Perez-Del-Pulgar, S.
    Forns, X.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 30 - 30
  • [23] Treatment of HBeAg-negative chronic hepatitis B
    Hadziyannis, SJ
    Papatheodoridis, GV
    Vassilopoulos, D
    SEMINARS IN LIVER DISEASE, 2003, 23 (01) : 81 - 88
  • [24] Severe acute exacerbation of HBeAg-negative chronic hepatitis B has good maintained response to lamivudine treatment
    Chan, H.
    Wong, V.
    Hui, A.
    Tsang, S.
    Chan, J.
    Chan, H.
    Wong, G.
    Sung, J.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S97 - S98
  • [25] Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients
    Papachrysos, Nikolaos
    Hytiroglou, Prodromos
    Papalavrentios, Lavrentios
    Sinakos, Emmanouil
    Kouvelis, Ioannis
    Akriviadis, Evangelos
    ANNALS OF GASTROENTEROLOGY, 2015, 28 (03): : 374 - 378
  • [26] The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients
    Peng, Chien-Wei
    Jeng, Wen-Juei
    HEPATOLOGY INTERNATIONAL, 2021, 15 (02) : 527 - 528
  • [27] Antiviral therapy leads to histological improvement in HBeAg-negative chronic hepatitis B patients
    Basyigit, Sebahat
    Sapmaz, Ferdane
    Yeniova, Abdullah O.
    ANNALS OF GASTROENTEROLOGY, 2015, 28 (04): : 506 - +
  • [28] Clinical Experience with Long-term Lamivudine Therapy to Determine the Adequate Duration of Treatment in Children and Adolescents with HBeAg-Negative Chronic Hepatitis B
    Kim, Jung-Mi
    Hong, Suk Jin
    Choi, Byung-Ho
    Chu, Mi Ae
    Cho, Seung Man
    Choe, Byung-Ho
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2009, 12 (01) : 23 - 29
  • [29] Predictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis B
    Guclu, Ertugrul
    Tuna, Nazan
    Karabay, Oguz
    Akhan, Sila
    Bodur, Hurrem
    Ceylan, Bahadir
    Demirdal, Tuna
    Demirdag, Kutbettin
    Demirturk, Nese
    Ekerbicer, Hasan
    Erol, Serpil
    Esen, Saban
    Evirgen, Omer
    Geyik, Mehmet Faruk
    Gunduz, Alper
    Karahocagil, Mustafa Kasim
    Kokoglu, Omer Faruk
    Ozdemir, Davut
    Ozgunes, Nail
    Sargin, Fatma
    Tosun, Selma
    Tutuncu, Ediz
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2014, 8 (12): : 1601 - 1608
  • [30] Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran
    Amir Houshang Mohammad Alizadeh
    Mitra Ranjbar
    Babak Karimi
    Saeed Hatami
    World Journal of Gastroenterology, 2006, (26) : 4203 - 4205
12345